Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 6/20 | 0.34 |
| ▸ | FABP3 | P05413 | 3/20 | 0.34 |
| ▸ | FABP4 | P15090 | 3/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24069733 | 0.83 | PIK3CA (0.37) | FFAR2MDM2NPSR1 | |
| SCHEMBL24069564 | 0.81 | SPR (0.46) | FABP3FABP4FABP5CYP2C9ALDH1A1 | |
| SCHEMBL25697994 | 0.79 | NPSR1 (0.45) | FABP3FABP4FABP5CYP2C9NPSR1 | |
| SCHEMBL25698228 | 0.78 | SPR (0.46) | FABP3FABP4FABP5CYP2C9ALDH1A1 | |
| SCHEMBL24070539 | 0.78 | SPR (0.44) | FABP3FABP4FABP5CYP2C9ALDH1A1 | |
| SCHEMBL24070559 | 0.78 | SPR (0.41) | FFAR2FABP3FABP4FABP5CYP2C9 | |
| SCHEMBL25698017 | 0.77 | FABP3 (0.50) | FABP3FABP4FABP5CYP2C9ALDH1A1 | |
| SCHEMBL24070789 | 0.76 | SPR (0.48) | FABP3FABP4FABP5CYP2C9SPR | |
| SCHEMBL24069217 | 0.76 | SPR (0.41) | FABP3FABP4FABP5CYP2C9SPR | |
| SCHEMBL25698661 | 0.73 | SMN1; SMN2 (0.35) | FABP3FABP4FABP5CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | FFAR2 3437/4885FABP3 4864/4885FABP4 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.